Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 414,719 shares of the biopharmaceutical company's stock after acquiring an additional 90,714 shares during the quarter. Fisher Asset Management LLC owned 0.33% of Halozyme Therapeutics worth $19,828,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $29,000. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth $69,000. Parkside Financial Bank & Trust lifted its position in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,028 shares during the last quarter. Finally, Centaurus Financial Inc. purchased a new stake in Halozyme Therapeutics during the 3rd quarter worth about $127,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HALO. Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Remove Ads

Halozyme Therapeutics Trading Up 1.4 %

HALO stock traded up $0.83 during trading on Friday, reaching $60.98. 1,491,605 shares of the stock traded hands, compared to its average volume of 1,304,860. The firm has a market capitalization of $7.51 billion, a PE ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The business's 50 day moving average price is $55.44 and its 200-day moving average price is $54.78. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company's stock, valued at $1,972,629.59. This represents a 12.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock worth $1,754,451 in the last 90 days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.